1887
Preview this article:

There is no abstract available.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.031013-0
2011-09-01
2021-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/9/1229.html?itemId=/content/journal/jmm/10.1099/jmm.0.031013-0&mimeType=html&fmt=ahah

References

  1. Amyes S. G. B., Walsh F. M., Bradley J. S. 2007; Best in class: a good principle for antibiotic usage to limit resistance development?. J Antimicrob Chemother 59:825–826 [View Article][PubMed]
    [Google Scholar]
  2. Brown S., Amyes S. G. B. 2006; OXA (β)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 57:1–3 [View Article][PubMed]
    [Google Scholar]
  3. Doumith M., Ellington M. J., Livermore D. M., Woodford N. 2009; Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63:659–667 [View Article][PubMed]
    [Google Scholar]
  4. Edwards J. R. 1995; Meropenem: a microbiological overview. J Antimicrob Chemother 36:Suppl. A1–17[PubMed] [CrossRef]
    [Google Scholar]
  5. Gehrlein M., Leying H., Cullmann W., Wendt S., Opferkuch W. 1991; Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. Chemotherapy 37:405–412 [View Article][PubMed]
    [Google Scholar]
  6. Girlich D., Poirel L., Nordmann P. 2009; CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli . Antimicrob Agents Chemother 53:832–834 [View Article][PubMed]
    [Google Scholar]
  7. Jacoby G. A., Mills D. M., Chow N. 2004; Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae . Antimicrob Agents Chemother 48:3203–3206 [View Article][PubMed]
    [Google Scholar]
  8. Kahan F. M., Kropp H., Sundelof J. G., Birnbaum J. 1983; Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother 12:Suppl. D1–35[PubMed] [CrossRef]
    [Google Scholar]
  9. Kumarasamy K. K., Toleman M. A., Walsh T. R., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske C. G. et al. 2010; Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602 [View Article][PubMed]
    [Google Scholar]
  10. Li J., Nation R. L., Turnidge J. D., Milne R. W., Coulthard K., Rayner C. R., Paterson D. L. 2006; Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601 [View Article][PubMed]
    [Google Scholar]
  11. Livermore D. M., Sefton A. M., Scott G. M. 2003; Properties and potential of ertapenem. J Antimicrob Chemother 52:331–344 [View Article][PubMed]
    [Google Scholar]
  12. Peleg A. Y., Seifert H., Paterson D. L. 2008; Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582 [View Article][PubMed]
    [Google Scholar]
  13. Poirel L., Nordmann P. 2002; Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Curr Pharm Biotechnol 3:117–127 [View Article][PubMed]
    [Google Scholar]
  14. Poirel L., Nordmann P. 2006; Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene bla OXA-58 in Acinetobacter baumannii . Antimicrob Agents Chemother 50:1442–1448 [View Article][PubMed]
    [Google Scholar]
  15. Turton J. F., Ward M. E., Woodford N., Kaufmann M. E., Pike R., Livermore D. M., Pitt T. L. 2006; The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii . FEMS Microbiol Lett 258:72–77 [View Article][PubMed]
    [Google Scholar]
  16. Walsh T. R., Toleman M. A., Poirel L., Nordmann P. 2005; Metallo-β-lactamases: the quiet before the storm?. Clin Microbiol Rev 18:306–325 [View Article][PubMed]
    [Google Scholar]
  17. Wiseman L. R., Wagstaff A. J., Brogden R. N., Bryson H. M. 1995; Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73–101 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.031013-0
Loading

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error